ABT vs. ALNY: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ABT and ALNY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
ABT’s market capitalization of 232.06 billion USD is substantially larger than ALNY’s 40.06 billion USD, indicating a significant difference in their market valuations.
ABT’s beta of 0.74 points to significantly higher volatility compared to ALNY (beta: 0.21), suggesting ABT has greater potential for both gains and losses relative to market movements.
| Symbol | ABT | ALNY |
|---|---|---|
| Company Name | Abbott Laboratories | Alnylam Pharmaceuticals, Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Devices | Biotechnology |
| CEO | Mr. Robert B. Ford | Dr. Yvonne L. Greenstreet M.B.A., M.D. |
| Price | 133.38 USD | 307.255 USD |
| Market Cap | 232.06 billion USD | 40.06 billion USD |
| Beta | 0.74 | 0.21 |
| Exchange | NYSE | NASDAQ |
| IPO Date | March 17, 1980 | June 1, 2004 |
| ADR | No | No |
Historical Performance
This chart compares the performance of ABT and ALNY over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Data is adjusted for dividends and splits.
- ABT: $13076.02 (30.76%)
- ALNY: $20007.15 (100.07%)
Profitability
Return on Equity
ABT
30.76%
Medical - Devices Industry
- Max
- 210.85%
- Q3
- 7.55%
- Median
- -28.09%
- Q1
- -129.75%
- Min
- -334.57%
ABT’s Return on Equity of 30.76% is in the upper quartile for the Medical - Devices industry, signaling a highly effective use of shareholder capital to drive profitability compared to most of its peers.
ALNY
-509.33%
Biotechnology Industry
- Max
- 160.48%
- Q3
- -7.20%
- Median
- -56.04%
- Q1
- -120.86%
- Min
- -282.47%
ALNY has a negative Return on Equity of -509.33%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Return on Invested Capital
ABT
19.13%
Medical - Devices Industry
- Max
- 27.07%
- Q3
- -0.15%
- Median
- -27.86%
- Q1
- -97.22%
- Min
- -235.17%
ABT’s Return on Invested Capital of 19.13% is in the upper quartile for the Medical - Devices industry, signifying a highly effective use of its capital to generate profits when compared to its peers.
ALNY
-2.79%
Biotechnology Industry
- Max
- 90.96%
- Q3
- -23.73%
- Median
- -52.59%
- Q1
- -101.56%
- Min
- -216.70%
ALNY has a negative Return on Invested Capital of -2.79%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
Net Profit Margin
ABT
31.89%
Medical - Devices Industry
- Max
- 75.48%
- Q3
- -4.73%
- Median
- -36.57%
- Q1
- -145.48%
- Min
- -351.20%
ABT’s Net Profit Margin of 31.89% is in the upper quartile for the Medical - Devices industry, signifying strong profitability and more effective cost management than most of its peers.
ALNY
-11.49%
Biotechnology Industry
- Max
- 3,408.18%
- Q3
- -60.78%
- Median
- -412.44%
- Q1
- -3,032.88%
- Min
- -7,417.79%
ALNY has a negative Net Profit Margin of -11.49%, indicating the company is operating at a net loss as its expenses exceed revenues.
Operating Profit Margin
ABT
16.97%
Medical - Devices Industry
- Max
- 36.12%
- Q3
- -0.16%
- Median
- -35.51%
- Q1
- -160.30%
- Min
- -370.58%
ABT’s Operating Profit Margin of 16.97% is in the upper quartile for the Medical - Devices industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
ALNY
-4.91%
Biotechnology Industry
- Max
- 3,462.86%
- Q3
- -79.64%
- Median
- -472.72%
- Q1
- -3,191.70%
- Min
- -7,857.88%
ALNY has a negative Operating Profit Margin of -4.91%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | ABT | ALNY |
|---|---|---|
| Return on Equity (TTM) | 30.76% | -509.33% |
| Return on Assets (TTM) | 16.58% | -6.40% |
| Return on Invested Capital (TTM) | 19.13% | -2.79% |
| Net Profit Margin (TTM) | 31.89% | -11.49% |
| Operating Profit Margin (TTM) | 16.97% | -4.91% |
| Gross Profit Margin (TTM) | 55.89% | 86.01% |
Financial Strength
Current Ratio
ABT
1.78
Medical - Devices Industry
- Max
- 11.44
- Q3
- 5.55
- Median
- 2.85
- Q1
- 1.55
- Min
- 0.01
ABT’s Current Ratio of 1.78 aligns with the median group of the Medical - Devices industry, indicating that its short-term liquidity is in line with its sector peers.
ALNY
3.04
Biotechnology Industry
- Max
- 19.64
- Q3
- 9.18
- Median
- 4.46
- Q1
- 2.01
- Min
- 0.00
ALNY’s Current Ratio of 3.04 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio
ABT
0.27
Medical - Devices Industry
- Max
- 1.95
- Q3
- 0.83
- Median
- 0.24
- Q1
- 0.07
- Min
- 0.00
ABT’s Debt-to-Equity Ratio of 0.27 is typical for the Medical - Devices industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
ALNY
11.28
Biotechnology Industry
- Max
- 0.86
- Q3
- 0.36
- Median
- 0.09
- Q1
- 0.02
- Min
- 0.00
ALNY’s Debt-to-Equity Ratio of 11.28 is exceptionally high, falling well outside the typical range for the Biotechnology industry. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates the company’s financial risk.
Interest Coverage Ratio
ABT
15.39
Medical - Devices Industry
- Max
- 43.93
- Q3
- 3.88
- Median
- -5.96
- Q1
- -22.92
- Min
- -61.44
ABT’s Interest Coverage Ratio of 15.39 is in the upper quartile for the Medical - Devices industry, signifying a strong and healthy capacity to meet its interest payments out of operating profits.
ALNY
-0.79
Biotechnology Industry
- Max
- 143.86
- Q3
- -5.85
- Median
- -29.74
- Q1
- -170.62
- Min
- -397.83
ALNY has a negative Interest Coverage Ratio of -0.79. This indicates that its operating earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | ABT | ALNY |
|---|---|---|
| Current Ratio (TTM) | 1.78 | 3.04 |
| Quick Ratio (TTM) | 1.27 | 2.98 |
| Debt-to-Equity Ratio (TTM) | 0.27 | 11.28 |
| Debt-to-Asset Ratio (TTM) | 0.16 | 0.31 |
| Net Debt-to-EBITDA Ratio (TTM) | 0.60 | -1.85 |
| Interest Coverage Ratio (TTM) | 15.39 | -0.79 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ABT and ALNY. These metrics are based on the companies’ annual financial reports.
Revenue Growth (YoY)
EPS Growth (YoY)
Free Cash Flow Growth (YoY)
Dividend
Dividend Yield
ABT
1.71%
Medical - Devices Industry
- Max
- 1.68%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ABT’s Dividend Yield of 1.71% is exceptionally high, placing it well above the typical range for the Medical - Devices industry. While this may seem attractive to income investors, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s future sustainability.
ALNY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALNY currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting all earnings back into the business, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio
ABT
28.92%
Medical - Devices Industry
- Max
- 43.20%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ABT’s payout ratio of 28.92% is in the upper quartile for the Medical - Devices industry. This reflects a generous dividend policy compared to its peers, favoring shareholder payouts over retaining capital.
ALNY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALNY has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This typically means all profits are being reinvested for growth.
Dividend at a Glance
| Symbol | ABT | ALNY |
|---|---|---|
| Dividend Yield (TTM) | 1.71% | 0.00% |
| Dividend Payout Ratio (TTM) | 28.92% | 0.00% |
Valuation
Price-to-Earnings Ratio
ABT
17.26
Medical - Devices Industry
- Max
- 97.30
- Q3
- 57.66
- Median
- 38.61
- Q1
- 14.67
- Min
- 0.18
ABT’s P/E Ratio of 17.26 is comparable to the norm for the Medical - Devices industry, suggesting its valuation is neither at a significant premium nor a discount to its peers.
ALNY
-147.73
Biotechnology Industry
- Max
- 94.36
- Q3
- 51.53
- Median
- 15.96
- Q1
- 6.14
- Min
- 0.00
ALNY has a negative P/E Ratio of -147.73, indicating it has a net loss. A negative P/E is not a reliable indicator for valuation comparisons.
Forward P/E to Growth Ratio
ABT
1.72
Medical - Devices Industry
- Max
- 4.34
- Q3
- 1.81
- Median
- 0.40
- Q1
- 0.07
- Min
- 0.00
ABT’s Forward PEG Ratio of 1.72 is typical for the Medical - Devices industry, suggesting its valuation is reasonably aligned with its growth prospects, consistent with sector norms.
ALNY
-40.07
Biotechnology Industry
- Max
- 1.10
- Q3
- 0.45
- Median
- 0.09
- Q1
- 0.02
- Min
- 0.00
ALNY has a negative Forward PEG Ratio of -40.07. This typically results from either negative earnings (a current loss) or forecasts of declining future earnings, making the ratio not meaningful for valuation purposes.
Price-to-Book Ratio
ABT
4.77
Medical - Devices Industry
- Max
- 12.47
- Q3
- 5.92
- Median
- 2.82
- Q1
- 0.95
- Min
- 0.00
ABT’s P/B Ratio of 4.77 reflects the benchmark for the Medical - Devices industry, indicating that its market valuation relative to its book value is standard for the sector.
ALNY
345.16
Biotechnology Industry
- Max
- 10.92
- Q3
- 4.88
- Median
- 1.80
- Q1
- 0.65
- Min
- 0.00
The P/B Ratio isn’t typically a primary valuation metric for companies in the Biotechnology industry.
Price-to-Sales Ratio
ABT
5.48
Medical - Devices Industry
- Max
- 17.05
- Q3
- 7.53
- Median
- 2.77
- Q1
- 1.03
- Min
- 0.01
ABT’s P/S Ratio of 5.48 is valued in line with its peers in the Medical - Devices industry, suggesting the market’s valuation of its sales is typical for the sector.
ALNY
17.06
Biotechnology Industry
- Max
- 141.58
- Q3
- 60.06
- Median
- 10.51
- Q1
- 2.88
- Min
- 0.00
ALNY’s P/S Ratio of 17.06 is valued in line with its peers in the Biotechnology industry, suggesting the market’s valuation of its sales is typical for the sector.
Valuation at a Glance
| Symbol | ABT | ALNY |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 17.26 | -147.73 |
| Forward PEG Ratio (TTM) | 1.72 | -40.07 |
| Price-to-Sales Ratio (P/S, TTM) | 5.48 | 17.06 |
| Price-to-Book Ratio (P/B, TTM) | 4.77 | 345.16 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 34.86 | -531.44 |
| EV-to-EBITDA (TTM) | 21.32 | -264.26 |
| EV-to-Sales (TTM) | 5.64 | 17.18 |